Cambrex Corporation is a life sciences company engaged primarily in the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to generic drug companies. Cambrex primarily supplies its products and services to pharmaceutical and generic drug companies. The Company's products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products and other fine custom chemicals derived from organic chemistry. Cambrex completed the sale of the businesses that comprised the Bioproducts and Biopharma segments in February 2007. In January 2008, the Company acquired ProSyntest AS, a privately held API research and development company located in Tallinn, Estonia. ProSyntest was renamed to Cambrex Tallinn.